This consensus report from the European Society for Blood and Marrow Transplantation (EBMT) gives an overview of clinical studies on the use of tyrosine kinase inhibitors (TKIs) to prevent relapse after allogeneic HCT for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The EBMT report makes practical recommendations for clinicians regarding the choice of TKI, treatment timing, and dosage, based on the consensus of experts.
Use of TKIs to Prevent Relapse after HCT for Patients with Ph+ ALL
Jul 2016